This paper reviews studies which have investigated the effect of anaesthetic agents on platelet function. The results of these studies suggest that halothane is the only agent in current use which inhibits platelet function in concentrations used clinically. Nitrous oxide appears to cause only a modest inhibition, while enflurane and isoflurane appear to have minimal or negligible effects. There is no current evidence that intravenous induction agents, opiates, or muscle relaxants affect platelet function. Reports indicate that local anaesthetic agents inhibit platelet aggregation, but only at concentrations far greater than peak plasma concentrations found during clinical use. Epidural anaesthesia may be associated with a reduction in platelet aggregation through a mechanism unrelated to direct local anaesthetic inhibition. The clinical significance of the effect of halothane on platelet function is not known. However, it is possible that halothane may affect bleeding or thrombotic complications in a similar manner to other 'anti-platelet' drugs.
anaesthetic agent per se affects intra-operative platelet function. Nevertheless, there have been numerous studies which have demonstrated an effect of anaesthetic agents on platelet function. Unfortunately, the results of many such studies have been conflicting, and the results of others have been inconclusive. The aim of this paper is to review previous studies which have examined the effects of anaesthetic agents on platelet function. Due to the complex nature of platelet activation, and the multitude of platelet function tests used in previous studies, a brief summary of platelet physiology and the more common platelet function tests will be included.
PLATELET PHYSIOLOGY There are several recent reviews of platelet function 1-3,8 and only a brief overview will be presented here. Platelets are smooth anucleate discoid cells which circulate in the blood for seven to ten days. Platelets are required for primary haemostasis which involves the formation of a haemostatic plug at sites of vascular injury. Platelets can be stimulated by collagen, or by a number of other agonists such as adenosine diphosphate (ADP), thrombin, or platelet activating factor (PAF). At high shear rates, such as those found in the arterial circulation, factor VIII related antigen/v on Willebrand factor (VIII Rag/ vWF) is required for binding of platelets to subendothelia l collagen. Stimulated platelets undergo an immediate shape change, and depending on the strength of stimulation, undergo a release reaction which results in the release of the contents of platelet granules. Platelets contain three types of granules: O-granules (dense bodies) which contain ADP, adenosine triphosphate (ATP), serotonin, and calcium ions; a-granules which contain thrombospon din, ~-thromboglob ulin (B-TG), platelet factor 4 (PF4), platelet derived growth factor, VIIIRaglvWF, and fibrinogen; and lysosomes which contain lysosomal enzymes. Very low concentrations of collagen or other agonists do not initiate the release reaction and result in a localised, reversible platelet aggregate. Higher concentrations of agonists activate the release reaction, which results in the stimulation of surrounding platelets and the formation of a larger irreversible platelet plug. There are at least three pathways to the release reaction in human platelets. The first involves the freeing of arachidonic acid from membrane phospholipi ds by low concentrations of collagen, ADP, or other agonists. The arachidonic acid is converted by cyclooxygenase to cyclic endoperoxides , most of which are unstable and are rapidly converted by thromboxane synthetase to thromboxane A2 (TXA 2 ). TXA2 acts as a calcium ionophore and increases cytosolic free calcium ion concentrations . This results in the release of granule contents. TXA2 has a short half-life and is rapidly converted by TXB 2 synthetase to TXB 2 . This pathway can be blocked by inhibitors of cyclo-oxygenas e. Cyclooxygenase is inactivated irreversibly by aspirin, and reversibly by other non-steroidal antiinflammatory drugs. 7 ,8 The second pathway requires higher concentrations of agonists and involves the release of diacyl-glycerol and inositoltriphosphate from membrane phospholipids . These compounds initiate a sufficiently brisk increase in cytosolic free calcium to promote the release reaction independently of the activation of the arachidonic acid pathway. A third pathway involves platelet activating factor which promotes the release reaction directly. Following the release reaction there are conformationa l changes in the platelet membrane which promote coagulant activity on the platelet surface. This function of platelets (platelet factor 3) contributes to the formation of an interdigitatin g fibrinous haemostatic plug or secondary haemostasis.
PLATELET FUNCTION TESTS
The diagnosis of platelet dysfunction is based primarily on history and physical findings. 2o ,21 However, the following laboratory tests are commonly used to confirm platelet abnormalities. 8,20-22
Platelet count
The normal platelet count is 150,000-45,00 0 per Ill. Abnormal bleeding rarely occurs if the platelet count is above 50,000 per Ill, and spontaneous bleeding is uncommon if the platelet count is above 20,000 per Ill. However, if platelet function is abnormal, prolonged or spontaneous bleeding can at higher platelet counts. 21 ,22
Bleeding time
The bleeding time is dependent on many variables such as length, depth, direction, and position of the incision, the venous pressure, and the degree of vasodilatation. 22 -24 Several of these factors are standardised using the template modification of the Ivy technique. 22 ,25 However, due to slight variations in methodology, each laboratory must establish a normal range for the exact method used. 22 Abnormal clinical bleeding is uncommon if the bleeding time is less than 10 minutes. The bleeding time can be performed at the bedside and is a sensitive measure of platelet plug formation. However, it is nonspecific and can be altered by defective vessel walls (such as in uraemia), by low levels of fibrinogen or VIIIRagl vWF, or by severe anaemia. 22
Platelet aggregation tests
Platelet aggregation tests are performed using a modified spectrophotom eter to measure the turbidity of 'platelet-rich' plasma. As platelet aggregation proceeds, more light is transmitted through the 'aggregometer ' and this can be calibrated and quantified. The most common measure of the aggregation response is the maximum height of the aggregation trace after a standard time (usually 3 minutes). Other measures include the threshold concentrations of agents required to induce a set amount of platelet aggregation, or the slope of the aggregation trace. Common aggregating agents include ADP, collagen, adrenaline, arachidonic acid, and thrombin. PAF and calcium ionophore 23187 are potent agonists which are used for research purposes. 22
Tests of the release reaction
The specific a-granule contents platelet factor 4 (a heparin neutralising factor 2 ,22), and ~ thromboglobul in (an inhibitor of prostacyclin 2 ,26) can be measured in plasma and are indices of in vivo platelet activation and release. The measurement of adenine nucleotides and 14C_ serotonin (O-granule contents) can be performed only in vitro. 22 
Viscoelastic measures of platelet function
Thromboelasto graphy and Sonoclot® analysis (Sienco Inc., Morrison, CO., U.S.A.) measure the viscoelastic properties of whole blood or recalcified Anaesthesia and Intensive Care, Vol. 19, No. 4, November, 1991 plasma during clot formation. 27 ,28 The maximum amplitude of the thromboelasto gram is a measure of the absolute strength of the blood clot and is in part dependent on platelet number and function. The 'peak' impedance of the Sonoclot"'" trace is also an index of platelet function. These viscoelastic measures often correlate poorly with routine coagulation tests. However, they have proved useful in the intra-operative management of patients with abnormal bleeding. 29 ,3o INHALATIONAL AGENTS
Laboratory studies:
In 1971 Ueda examined the effects of several volatile anaesthetic agents on platelet aggregation in vitro. 3l He found that clinically used concentration s of methoxyfluran e, halothane, diethylether, and nitrous oxide all inhibited ADP(O.l-1.0~M )-induced aggregation of canine platelets. In 1979 Bjoraker examined the effect of halothane on ADP(50JlM)-i nduced aggregation of human plateletsY He found that halothane induced a dose-related and reversible suppression, but that this effect was only significant at halothane concentrations above 5%. However, he used a very high ADP concentration (5 to 50 times greater than the concentration used by most investigators 22 ) . In 1980 Dalsgaard-Nie lsen and Gormsen examined the effect of halothane on platelet aggregation, and serotonin uptake and release, in human platelets. 33 They found that halothane inhibited ADP(0.25-5.0JlM)-induce d platelet aggregation in a doserelated manner. Halothane 2% produced complete inhibition. The inhibition lasted less than ten minutes post-exposur e at low halothane concentrations « 1 %), but was only partially reversed at ten minutes at higher halothane concentrations . They found that halothane reduced the rate, but not the total amount of serotonin taken up and released following exposure of platelets to ADP(5.0~M). This suggested that halothane did not reduce the storage potential of platelet dense bodies. Also in 1980, Walter et al. demonstrated that halothane (0.5-10%) increased platelet adenylcyclase activity in a dose-related manner (93% increase in activity by halothane 5%), and reduced platelet aggregation in vitro. 34 In the same study, phoshodiestera se activity was not affected by halothane. Waiter et al. postulated that halothane inhibited platelet aggregation by stimulating adenylcyclase activity, thus increasing platelet c-AMP levels.
In 1983 Cambria et al. used a technique of yimaging to examine the effect of halothane anaesthesia on platelet deposition on polytetrafluoro ethylene arterial grafts in dogs. 35 They found that halothane significantly decreased Anaesthesia and Intensive Care, Vol. 19, No. 4. November, 1991 platelet uptake on the grafts, but that this effect was reversible within 24 hours.
In 1986 Fauss et al. investigated the effects of isoflurane and nitrous oxide on aggregation of human platelets in vitro and in vivo. 36 Nitrous oxide (80%) reduced ADP(5~M)-in duced platelet aggregation from 70.2% (control) to 58.3% in vitro (P < 0.05). The addition of isoflurane 1.6% did not result in a further reduction in platelet aggregation. However, isoflurane 1.6% alone reduced platelet aggregation from 73.4% (control) to 69.2% (P< 0.05). The combination of nitrous oxide 60% and isoflurane 1-2% produced a minimal ( < 10%), but statistically significant reduction of ADP(5~M and 10IlM)-induce d platelet aggregation in vivo.
A recent study by Bertha et al. reported an interesting and potentially important effect of halothane on acute thrombus formation in artificially stenosed coronary arteries in dogs. 37 Cyclical flow reductions occur in stenosed dog and pig coronary arteries due to cycles of acute thrombus formation and breakdown. 37 ,38 These flow reductions are exacerbated by adrenaline. Bertha et al. found that halothane abolished both spontaneous and adrenaline-in duced cyclic coronary flow reductions. However, enflurane and isoflurane had no effect. The cyclic flow reductions recurred within minutes of stopping halothane. The authors indicated that although the significance of their findings was as yet unknown, it was possible that halothane has a protective effect against acute thrombus formation in stenosed coronary arteries.
Clinical studies:
In 1971 O'Brien et al. studied platelet function in ten patients undergoing major thoracic procedures. 39 They found that during surgery there was a gross reduction in the aggregation response to both ADP(0.2-2IlM ) and collagen which persisted one to three hours postoperatively . They did not identify the inhalational anaesthetic agents used, although they indicated that some patients received halothane. This study was one of the first to demonstrate that platelet aggregation did not increase during surgery, but rather decreased. In 1977 Kokores et al. performed several platelet function tests on patients before and during abdominal surgery for gastro-intes tinal carcinoma. 4o Patients were anaesthetised with thiopentone followed by halothane 0.3-1.5% and nitrous oxide 60-66% in oxygen (all anaesthetic concentrations stated in clinical studies are inspired). They found that 30 minutes into the operation the template bleeding time was significantly increased (4.6 mins vs 3.9 min preinduction, P < 0.05). Platelet aggregation induced by ADP( 1.0-2IlM) was reduced by about 25%.
These changes were similar at three hours into the operation. Minor changes in collagen-and adrenaline-induced platelet aggregation were also noted.
In 1979 Lichtenfeld et al. examined platelet function in twelve patients undergoing minor surgery. 41 Anaesthesia was induced with thiopentone and maintained with halothane or enflurane 0.5-1.0%, and nitrous oxide in oxygen. During surgery there were slight reductions in ADP( 1.0-5.0J.LM)-induced platelet aggregation but the changes were not significant. The study did not differentiate between patients receiving halothane or enflurane. Dalsgaard-Nielsen and Gormsen suggested that the reason Lichtenfeld et al. did not observe an effect of halothane was because the halothane in their blood samples had evaporated during preparation for aggregometry. 33 In 1980 Gotta et al. investigated the effect of enflurane and fentanyl anaesthesia on platelet function in thirty surgical patients. 42 Patients received nitrous oxide 60% in oxygen and either enflurane 0.5-2.0%, or intermittent boluses of fentanyl IV. They found that there were no significant changes in ADP(20J.LM)-or collagen (0.26 mg.ml-I)-induced platelet aggregation in either group, although there was considerable variability in response in both groups. The thromboelastographic pattern was also unchanged.
In 1981 Dalsgaard-Nielsen et al. examined platelet aggregation and bleeding times in ten patients anaesthetised with halothane 1 % and nitrous oxide 66% in oxygen for minor surgery. 43 They found that bleeding time increased significantly during surgery (9.9 min vs 6.4 min preoperatively, P< 0.005). There was also a reduction in the sensitivity of platelets to aggregation by ADP in vitro, and this change correlated closely with the increase in bleeding times. The authors attributed the observed changes to a direct effect of halothane on platelet function. However, they also remarked on a wide variation in both bleeding times and platelet responses in their study.
In 1984 Fyman et at. examined the effect of volatile anaesthetic agents on bleeding times in elective surgical patients. 44 They randomised 51 patients to receive either halothane 0.5-2.0% in oxygen, enflurane 1.0-3.5% in oxygen, isoflurane 1.2-3.0% in oxygen, or nitrous oxide 66% in oxygen plus fentanyl boluses IV. Bleeding times were measured using a template device. Blood pressure and heart rate were maintained at ±20% of preoperative values. They found that there was considerable variability in the responses within each group. However, in the halothane group there was an average 33% increase in bleeding time (P < 0.01). There was a 19% increase in bleeding time in the N 20-fentanyl group but this change was not statistically significant. There was no change in mean bleeding time in either the enflurane or the isoflurane groups. The authors interpreted their findings as indicating an in vivo effect of halothane on platelet function, and cautioned against the use of halothane in situations where optimal haemostasis was critical. They argued that the increase in bleeding times in the halothane group were not due to anaesthetic-induced vasodilation alone, because no change in bleeding times was observed in either the enflurane or isoflurane group.
In 1987 Sweeney and Williams examined the effect of halothane on platelet function in children undergoing major craniofacial surgery or conservative dental surgery.45 They found that ADP-, collagen-and adrenaline-induced platelet aggregation were reduced intra-operatively in both groups. In 1988 Rosen et at. compared the effects of halothane, enflurane, and isoflurane on platelet function in 108 elective surgical patients. All patients also received thiopentone and nitrous oxide. 46 A Sonoclof 8 analyser 28 was used to determine the viscoelastic properties of blood during clot formation. It was found that all three agents induced platelet dysfunction, but that halothane produced the greatest changes.
There has been no published report on the effect of the newer volatile anaesthetic agents, sevoflurane and desflurane, on platelet function.
INTRAVENOUS AGENTS

Laboratory studies:
In 1978 patients received pancuronium bromide intraoperatively without a significant change in platelet aggregation. 42 In the study by Hines and Barash, the control group received pancuronium to maintain muscle relaxation but no changes in bleeding time or platelet aggregation were observed. 19
LoCAL ANAESTHETICS Laboratory studies:
In 1962 O'Brien, while investigating the processes of adhesion and aggregation of platelets, noted that cocaine (2.5 X 1O-3M), procaine In 1981, Luostarinen et al. examined the antithrombotic effects of lignocaine (2%), its metabolite monoethylglycine xylidide (2%), tocainide (2%), and bupivacaine (0.5%) on laserinduced microvascular injury in hampsters. 56 They found that the topical application of these compounds inhibited thrombus formation, and promoted the restoration of blood flow following microvascular injury.
In 1985, Borg and Modig examined the effect of lignocaine, bupivacaine, and tocainide on ADP(1.0J.1M)-and collagen(1.0J.1g.ml-I )-induced platelet aggregation in vitro. 57 They incubated the local anaesthetics with platelets for either 5 or 45 minutes prior to aggregometry. They found that after five minutes lignocaine and bupivacaine (lOJ.1g.ml-l ) inhibited platelet aggregation slightly, whereas a concentration of25 J.1g.ml-1 was required to inhibit platelet aggregation more distinctly. Increasing the incubation time to 45 minutes increased the percentage inhibition. Tocainide 100 ~g.ml-I also inhibited platelet aggregation. Increasing the ADP concentration to 10 J.1M overcame the inhibitory effect of all three agents. The authors noted that the concentrations of the local anaesthetics required to inhibit platelet aggregation in vitro were much higher than the peak plasma concentrations that occur in vivo. 58·60
In 1989 O'Doom et al. found that bupivacaine 10-25 Ilg.ml-1 inhibited ADP(1.0-2.0IlM)-and collagen(0.4llg.ml-1)-induced platelet aggregation in vitro. 6 I Bupivacaine 25 Ilg.ml-1 also reduced f3-TG release. However, bupivacaine 2Ilg.ml-1 (the usual upper limit in plasma during clinical use 59) had no effect on platelet aggregation or 13-TG release. Pipecoloxylidide, the principal metabolite of bupivacaine, also had no effect on platelet aggregation or f3-TG release. Also in 1989, Grant et al. examined the effect of bupivacaine, lignocaine, and 2-chloroprocaine on maternal and neonatal platelet function in vitro. 62 Neonatal platelets were more susceptible to the effect of local anaesthetics than maternal platelets. However, neither was affected by local anaesthetic concentrations likely to occur in plasma during clinical use. The authors concluded that epidural anaesthesia with these three agents was unlikely to affect either maternal or neonatal platelet function in vivo. Clinical studies:
In 1986 Henny et al. examined the effect of epidural bupivacaine on the haemostatic system in patients undergoing transurethral resection of the prostate gland. 63 They found that ADP(I.OIlM)and collagen(O.4llg. ml-1 )-induced platelet aggregation was inhibited in patients receiving epidural anaesthesia with 0.5% bupivacaine. In 1988 O'Doom et al. also reported that platelet aggregation was inhibited in patients receiving epidural anaesthesia with bupivacaine. 64 In their study, a peak plasma bupivacaine concentration of 470±270r]g.ml-1 occurred thirty minutes following bupivacaine administration. This concentration was much lower than the concentration of bupivacaine required to inhibit platelet aggregation in vitro. O'Doom et al. speculated that the intracellular concentration of bupivacaine in platelets might be higher than in the plasma, and that this might explain the observed inhibition of platelet aggregation at low plasma bupivacaine concentrations.
In 1989 Nielsen et al. examined collagen-induced platelet aggregation and TXB 2 synthesis in plasma from patients undergoing either general or epidural anaesthesia for arthroscopic meniscectomy. 65 They found that epidural anaesthesia with bupivacaine was associated with an increase in the threshold collagen concentration required to induce platelet aggregation, but the change was not significant. TXB 2 synthesis decreased in patients receiving epidural but not general anaesthesia. The addition of epidural morphine augmented the changes in the epidural group.
DISCUSSION
Injury to blood vessels initiates a series of reactions which results in the formation of a blood clot. Following initial local vasoconstriction there is a rapid formation of a platelet plug at the site of vascular injury. Fibrin deposition then commences through activation of either the intrinsic or extrinsic pathway. Abnormal bleeding may result from defects in the vessel wall, from abnormalities in platelet numbers or function, or from defective coagulation. 8 ,20,21 During surgery, bleeding may occur from any of the above factors or from incomplete surgical haemostasis. On the other hand, excessive coagulation or thrombosis may occur peri-operatively if there are abnormalities in vessel walls, in blood components, or in local blood flOW. 21 ,66 At low shear rates such as in the venous circulation, thrombosis may occur with the activation of relatively few platelets, because aggregatory and clotting factors accumulate and are not diluted. 21 However, in the arterial circulation, a much larger number of platelets must be activated for propagation of thrombus. 21 In this way platelet dysfunction has a greater impact on the incidence of arterial thrombosis than it does on venous thrombosis.
The central role of platelet activation in arterial thrombosis is underscored by the widespread use of anti-platelet drugs to reduce the morbidity from No effect 0. No effect § 1.6 30% inhibition (P < 0.025) §Halothane may have evaporated during preparation of samples 43 cerebrovascular or coronary artery disease.4-8 Of particular importance is the recognition that myocardial infarction is frequently a result of coronary artery thrombosis, and is not always precipitated by an imbalance in myocardial oxygen supply and demand. 67 This has implications for anaesthetists, because in the management of patients with coronary artery or cerebrovascular disease it may be important to continue 'anti-platelet' therapy through the peri-operative period. Moreover, it is possible that anaesthetic agents that have 'anti-platelet' effects protect against intravascular thrombosis during surgery.
The results of the numerous studies on the effect of anaesthetic agents on platelet function indicate that the only agent in current use that alters platelet function in concentrations used clinically is halothane. The effect of halothane has been demonstrated using platelet aggregometry in vitro and in vivo (Tables 1, 2). The inhibition of platelet aggregation occurs mostly with low concentrations of ADP, which suggests that halothane inhibits the arachidonic acid pathway to the release reaction. Halothane also increases bleeding times (Table 3) , and alters platelet deposition on artificial arterial grafts. 35 More importantly, it has been shown that halothane protects against thrombus formation in stenosed coronary arteries in dogsY Many of these studies indicate that the magnitude of the effect of halothane on platelets varies between patients. However, an overall inhibitory effect has been demonstrated in almost every study that has examined the effect of halothane on platelet function.
In contrast, the other volatile agents in current use, enflurane and isoflurane, do not appear to significantly alter platelet function. Nitrous oxide appears to have only a modest effect (Table 4 ). Moreover, there is no current evidence that clinically used doses of intravenous induction agents, opioids, or muscle relaxants affect platelet function. It is not known how halothane affects platelet function. However, data from WaIter et at. suggests that it is by stimulating platelet adeny1cyclase. 34 Several in vitro studies indicate that local anaesthetic agents inhibit platelet aggregation, but only at concentrations far greater than those likely to occur in plasma during clinical use (Table 5) . However, recent studies suggest that epidural anaesthesia per se may be associated with an inhibition of platelet aggregation despite subinhibitory plasma concentrations of local anaesthetic. 63 -65 The mechanism by which epidural anaesthesia reduces platelet aggregation in this manner is not known. Nevertheless, it is possible The clinical significance of the effect of halothane on platelet function is not clear. Halothane appears to have similar effects on platelet aggregation and bleeding time to other 'anti-platelet' drugs. Therefore it is possible that halothane may contribute to abnormal bleeding in a similar manner to other 'anti-platelet' drugs, [76] [77] [78] or may reduce the incidence of thrombotic complications in a similar manner to other 'anti-platelet' drugs. 4 -7 ,79 However, the 'anti-platelet' effect of halothane appears to be short-lived and it would only be active intraoperatively. These considerations are theoretical at present and prospective studies are required to determine whether halothane affects the incidence of bleeding or thrombotic complications in clinical practice. Nevertheless, all anaesthetists should be aware of the potential 'anti-platelet' effects of halothane.
In summary, it appears that halothane has a doserelated, reversible, inhibitory effect on platelet function. This effect occurs at concentrations used clinically. Nitrous oxide also has a modest inhibitory effect, but enflurane and isoflurane do not appear to significantly alter platelet function. There is no current evidence that intravenous induction agents, opioids, or muscle relaxants affect platelet function. Local anaesthetics inhibit platelet aggregation, but only at much higher concentrations than occur in vivo. Epidural anaesthesia per se may be associated with an inhibitory effect on platelet aggregation through a mechanism independent of direct local anaesthetic inhibition. The clinical significance of the effect of halothane on platelet function is not known but deserves further study.
